Pfizer Venture Investments

Pfizer Venture Investments is a venture capital firm in New York that invests in emerging companies that are developing transformative medicines and technologies. Founded 2004 in New York, United States, this corporate venture capital firm is the venture capital arm of Pfizer Inc. It funds Series A, Series B, Series C, and Post-IPO Equity rounds. Its portfolio companies include Cortexyme, Metabomed, Triplet Therapeutics, ImmunOs Therapeutics, and ImCheck Therapeutics. As of February 2020, Pfizer Venture Investments has made 93 investments. Their most recent investment was on Dec 19, 2019, when Metabomed raised $12.5M. Pfizer Venture Investments has had 28 exits, the most notable of which include Cortexyme, CytomX Therapeutics, and Neuronetics. The company has raised a single venture fund, Fund I. This fund was announced on Jun 6, 2018 and raised a total of $600M.

The company invests in companies within Pfizer's core therapeutic areas (Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines). Focus also includes neuroscience investments.

Pfizer Ventures, also known as Pfizer Venture Investments, is a venture capital firm founded in 2004. The firm is a subsidiary of Pfizer. It is based in New York City, New York. As of March 2019, the firm has 45 active companies in its portfolio and has sold off its ownership in 58 companies. Its most recent investment is in Imara on March 2019, a company developing therapeutics for individuals with sickle cell diseases.

Pfizer Ventures focuses on funding companies in the field of bio-pharmaceuticals and neuroscience. The firm primarily seeks to fund companies that are based in the United States, although it also allocates 20% of its investments for non-U.S. companies. It finances companies at various stages, from early to growth. Since its conception, it has managed to collect $600 million from one funding round held in June 2018.